Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics
MedComm – Oncology · 2025-09 · 4 (3)
DOI: 10.1002/mog2.70030 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm – Oncology, online erschienen am 07.07.2025. Verfasst von Han Sun und 10 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 441 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune checkpoints, the key gatekeepers of immune homeostasis, have become the central targets of modern cancer immunotherapy. These regulatory pathways, composed of co‐suppressive and co‐stimulatory molecules, enable the immune system to distinguish between self and non‐self while preventing excessive tissue damage. However, tumor cells strategically block these protective mechanisms through aberrant expression of checkpoint ligands, creating an immunosuppressive microenvironment that promotes tumor immune evasion and metastatic progression. Yet, immune checkpoint therapy is not universally applied due to its specific mechanisms. This review systematically describes the immune checkpoints that function on various types of immune cells, as well as their molecular structure and functional diversity, and elucidates their role in achieving tumor immune escape. We analyze the clinical translation of immune checkpoint inhibitors (ICIs) and their combination therapies. In addition, we combine preclinical findings with clinical trial data to provide a comprehensive framework for understanding the mechanisms of action and clinical applications of immune checkpoints, as well as to present the challenges in terms of immune‐related adverse events of ICIs. This review provides a valuable perspective for developing next‐generation immunotherapies and optimizing personalized treatment strategies.
Zitieren
APA
Sun, H., Huang, D., Zhang, H., Dong, M., Wang, S., Sun, M., Liu, J., Wang, Y., Qu, X., Li, X., & Yang, Z. (2025). Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics. MedComm – Oncology, 4(3). https://doi.org/10.1002/mog2.70030
Vancouver
Sun H, Huang D, Zhang H, Dong M, Wang S, Sun M, et al. Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics. MedComm – Oncology. 2025;4(3). doi:10.1002/mog2.70030
BibTeX
@article{Sun2025,
author = {Sun, Han and Huang, Dan and Zhang, Huiling and Dong, Mingyuan and Wang, Simiao and Sun, Man and Liu, Jiayi and Wang, Yiqi and Qu, Xiaojie and Li, Xuefeng and Yang, Zhaogang},
title = {Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics},
journal = {MedComm – Oncology},
year = {2025},
volume = {4},
number = {3},
doi = {10.1002/mog2.70030}
}
EUVIMED